Phase 1/2 Safety, Pharmacokinetic, and Antitumor Activity Study of G1T38 in Combination With Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer After Endocrine Failure

Trial Profile

Phase 1/2 Safety, Pharmacokinetic, and Antitumor Activity Study of G1T38 in Combination With Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer After Endocrine Failure

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Jul 2018

At a glance

  • Drugs Fulvestrant (Primary) ; G1T 38 (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors G1 Therapeutics
  • Most Recent Events

    • 05 Jun 2018 Preliminary (n=24) phase 1b results, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2018 According to a G1 Therapeutics media release, the company expects to enrol 30 participants in the Phase 2 expansion by the end of 2018, with data reading out in 2019.
    • 02 Jun 2018 Interim results (n=33; cut-off date 1 May 2018) presented in a G1 Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top